**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
5% Chance
$135,595 Vol.
$135,595 Vol.
31. Dez. 2026
5% Chance
$135,595 Vol.
$135,595 Vol.
31. Dez. 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Markt eröffnet: May 4, 2026, 10:39 AM ET
Volumen
$135,595Enddatum
1. Jan. 2027Markt eröffnet
May 4, 2026, 10:39 AM ETAbwickler
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volumen
$135,595Enddatum
1. Jan. 2027Markt eröffnet
May 4, 2026, 10:39 AM ETAbwickler
0x65070BE91...**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen